CFO
Andrew D. Dickinson is the Chief Financial Officer (CFO) of Gilead Sciences, Inc. (NASDAQ: GILD), a position he has held since November 1, 2019.[[1]](https://fintool.com/app/research/companies/GILD/people/andrew-d-dickinson)[[2]](https://www.gilead.com/news/news-details/2019/gilead-sciences-appoints-andrew-dickinson-as-chief-financial-officer)[[3]](https://www.gilead.com/company/leadership/andrew-dickinson) Aged 55, he oversees the company's global finance, corporate development, information technology, operations, and strategy, having joined Gilead in 2016 initially as Head of Corporate Development & Strategy, where he led licensing, partnerships, acquisitions, and investments into new therapeutic areas.[[1]](https://fintool.com/app/research/companies/GILD/people/andrew-d-dickinson)[[3]](https://www.gilead.com/company/leadership/andrew-dickinson) Under his leadership, Gilead achieved $28.6 billion in total product sales in 2024 (up 6% year-over-year), returned $5.1 billion to shareholders via dividends and repurchases, and delivered a 19% total shareholder return exceeding peer indices.[[1]](https://fintool.com/app/research/companies/GILD/people/andrew-d-dickinson) Recently, as a corporate insider, he sold 3,000 shares on January 15, 2026, at $124.31 per share under a Rule 10b5-1 plan, retaining 150,503 shares directly.[[6]](https://www.investing.com/news/insider-trading-news/gilead-sciences-cfo-dickinson-sells-372930-in-stock-93CH-4453070)
Dickinson's career highlights include nine years at Lazard Frères & Co. as Global Co-Head of Healthcare Investment Banking, advising on M&A and financing, and earlier roles as General Counsel and Vice President of Corporate Development at Myogen Inc., a cardio-focused biotech acquired by Gilead in 2006.[[1]](https://fintool.com/app/research/companies/GILD/people/andrew-d-dickinson)[[2]](https://www.gilead.com/news/news-details/2019/gilead-sciences-appoints-andrew-dickinson-as-chief-financial-officer)[[3]](https://www.gilead.com/company/leadership/andrew-dickinson) He holds a B.A. in molecular, cellular, and developmental biology from the University of Colorado Boulder and a J.D. from Loyola University Chicago.[[1]](https://fintool.com/app/research/companies/GILD/people/andrew-d-dickinson) Dickinson also serves on boards including Galapagos NV, Sutter Health, and formerly Fosun Pharma–Kite JV.[[1]](https://fintool.com/app/research/companies/GILD/people/andrew-d-dickinson)
View full insider profile →
